MUNICH--(BUSINESS WIRE)--CatalYm today announced treatment of the first patients in a series of phase 2a cohorts targeting solid tumors, initiating phase 2 development of CTL-002. The trial will ...
First report to show link between GDF-15 and LFA-1/ICAM-1 cell adhesion axis in cancer, resulting in impaired infiltration of T cells into the tumor microenvironment First report to show link between ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback